

This is the author's manuscript



#### AperTO - Archivio Istituzionale Open Access dell'Università di Torino

### Preoperative staging of Rectal Cancer using Magnetic Resonance Imaging: comparison with pathological staging

Original Citation:	
Avoilability	
Availability:	cinco 2017 05 17T11.52.077
This version is available http://hdl.handle.net/2318/1635341	since 2017-05-17T11:52:07Z
Published version:	
DOI:10.23736/S0026-4733.17.07392-8	
Terms of use:	
Open Access	
Anyone can freely access the full text of works made available a under a Creative Commons license can be used according to the of all other works requires consent of the right holder (author or protection by the applicable law.	e terms and conditions of said license. Use

(Article begins on next page)

## Minerva Chirurgica EDIZIONI MINERVA MEDICA

#### **ARTICLE ONLINE FIRST**

This provisional PDF corresponds to the article as it appeared upon acceptance.

A copyedited and fully formatted version will be made available soon.

The final version may contain major or minor changes.

# Preoperative staging of Rectal Cancer using Magnetic Resonance Imaging: comparison with pathological staging

Riccardo FALETTI, Marco GATTI, ALBERTO AREZZO, Silvia STOLA, Maria Chiara BENEDINI, Laura BERGAMASCO, Mario MORINO, Paolo FONIO

Minerva Chirurgica 2017 May 11 DOI: 10.23736/S0026-4733.17.07392-8

Article type: Original Article

© 2017 EDIZIONI MINERVA MEDICA

Subscription: Information about subscribing to Minerva Medica journals is online at:

http://www.minervamedica.it/en/how-to-order-journals.php

Reprints and permissions: For information about reprints and permissions send an email to:

journals.dept@minervamedica.it - journals2.dept@minervamedica.it - journals6.dept@minervamedica.it

#### **TITLE**

Preoperative staging of Rectal Cancer using Magnetic Resonance Imaging: comparison with pathological staging

#### **AUTHORS**

Riccardo Faletti, MD<sup>1</sup>; Marco Gatti, MD<sup>1</sup>; Alberto Arezzo, Prof.<sup>2</sup>; Silvia Stola, MD<sup>1</sup>; Maria Chiara Benedini, MD<sup>1</sup>; Laura Bergamasco, Prof.<sup>3</sup>; Mario Morino Prof.<sup>2</sup>; Paolo Fonio, Prof.<sup>1</sup>

#### **AFFILIATIONS**

- 1. Department of Surgical Sciences, Radiology Institute, University of Turin, Turin, Italy.
- 2. Department of Surgical Sciences, University of Turin, Turin, Italy.
- 3. University of Turin, Turin, Italy.

#### **CORRESPONDING AUTHOR**

Marco Gatti

marcogatti17@gmail.com

Via Genova 3, 10126 Torino

tel: +39 011 6336622

fax: +39 011 6960310

#### **ABSTRACT**

**BACKGROUND**: To evaluate the accuracy of Magnetic Resonance (MR) in loco-regional staging of rectal cancer by comparing the MR results with histologic findings, considered as standard reference.

**METHODS**: Between July 2013 and March 2015, fifty-two patients, 27 (51.9%) males, age 66.75±13.77 years, with rectal cancer, were staged preoperatively with MR and proceeding straight to surgery. Two observers with experience in abdominal MR independently reviewed the images. T stage and N stage were evaluated according to the 7<sup>th</sup> edition of TNM classification. The estimate of Ln probability of malignancy (low, moderate, high) was based on nodal size, border contour and signal intensity and comparison between ADC value of the Ln's belonging to the three different classifications were performed. Statistical testing included Cohen's kappa coefficient, Mann-Whitney's, Kruskal-Wallis, chi-square, Fisher's exact test and Receiving Operating Characteristics curve.

**RESULTS**: MR correctly assessed T stage in 47/52 cases (90.4%; k<sub>w</sub>=0.89±0.06), with interoperator concordance of k=0.81±0.08. For Ln staging, concordance between estimate of high probability malignancy and pathology was k<sub>w</sub>=0.62±0.11. ADC was significantly different for the malignancy probability three grades of estimated (p=0.0003), decreasing  $1.227\pm0.298\times10^{-3}$  mm<sup>2</sup>/s  $1.120\pm0.306\times10^{-3}$  mm<sup>2</sup>/s (low) to (moderate) and finally 0.818±0.168×10<sup>-3</sup>mm<sup>2</sup>/s (high). The ROC curve procedure established the good ability of ADC to discriminate high malignancy Ln's (AUC=0.88) with cut-off at  $<1\times10^{-3}$  mm<sup>2</sup>/s. The percentage of high malignancy Ln's in the lateral pelvic space was higher than in other sites (55.6% vs. 17.6%, p=0.0003).

**CONCLUSIONS**: MR is an accurate imaging method in T staging and N staging of rectal cancer: prediction of N was improved by considering dimension, morphology and signal characteristic and the ability of ADC to identify high probability malignant nodes underlines its importance in the diagnostic process.

**Key words**: Rectal cancer – Lymph node – Neoplasm staging – Magnetic Resonance Imaging – Diffusion Magnetic Resonance Imaging.

#### INTRODUCTION

Colorectal cancer is a common neoplastic disease, representing the third leading cause of cancer death [1]. Unfortunately, only 40% of patients with colorectal cancer get diagnosed when the disease is still at a local stage [2]. In fact, about half of them are affected by rectal cancer, their survival and risk for local recurrence being highly influenced by the presence of lymph nodes (Ln) metastasis (MTS) [3], as observed in up to 2/3 of patients [4,5].

In case of suspected rectal cancer international guidelines recommend Magnetic Resonance (MR) as fundamental for primary staging, because of its good accuracy for tumour (T) staging, being EUS preferred only in early stages suitable for local excision [6,7] and CT to identify possible distant MTSs [8]. Studies which investigated the ability of MR to predict also Ln involvement in rectal cancer [6,9-13], did not converge on uniformly accepted criteria on how to define Ln positivity [12], and how to assess it on the basis of morphologic criteria as dimension, spiculated or indistinct border and mottled heterogeneous appearance [4,5]. Diffusion Weighted Imaging has been considered effective in the detection of Ln [9], but failing in its characterization [11]. A few authors investigated Ln specific contrast agents [13], without however reaching a general consensus on their usefulness [14].

The aim of our study was to evaluate the accuracy of MR in the loco-regional staging of rectal cancer by comparing its results to pathology findings, considered as standard reference, avoiding the confounding factor of neoadjuvant therapy between initial MR staging and pathology examination of the surgical specimen.

#### **MATERIALS AND METHODS**

Between July 2013 and March 2015, a total of fifty-two consecutive patients, 27 (51.9%) males, mean age 66.7±13.7 years, with histologically proven rectal cancer, underwent a multiparametric rectal MR as part of an institutional standard work up before undergoing to surgery without neo-adjuvant therapy. Reasons for not performing chemo-radiotherapy before surgery in pT3 and pT4 Ln positive patients were advanced age, location of tumour between 12 and 16 cm from the anal verge, or the patient's preference.

At the moment of the MR examination, all patients were informed about the possible use of their data for study purposes, and signed an informed consent form. Patients' information was anonymized prior to the analysis. The study is a retrospective trial without any study-related clinical intervention and conforms to the Helsinki Declaration of 1975 and subsequent modifications.

#### MR protocol

The MR examination was performed by means of a 1.5 T (Achieva, version 2.6, Philips Medical Systems, Eindhoven, The Netherlands) with body coil phased array (16-channel Sense XL Torso). MR protocols consisted of a T2-weighted fast spin-echo sequence. Sagittal sequences were used to determine the longitudinal tumour axis in order to angle the axial and coronal planes as much as possible perpendicular and parallel to the tumour axis. Axial DWI was performed with a free-breathing single-shot echo planar imaging sequence immediately after the routine sequences. b 0, 300 and 600 s/mm² were used.

#### **Imaging analysis**

MR Extended Work Space 2.6.3.2 2009 software (Philips Medical Systems) was used for imaging interpretation.

Two observers (M.G. and S.S.) with experience in abdominal MR independently reviewed all images in a randomized and blinded way and classified the primary tumour according to the 7<sup>th</sup> edition of TNM classification [15]. Discordant readings were examined and discussed with a senior radiologist (R.F.) to reach a general consensus.

For nodal staging, the Ln estimate probability of malignancy was based on: 1) dimension (≥5 mm), 2) irregular border contour and 3) inhomogeneous signal intensity. The absence of all previous characteristics was considered at low probability of malignancy (P1); the presence of only one of these features was considered at moderate probability of malignity (P2); the presence of two or more features was considered at high probability of malignancy (P3). For each Ln the Apparent Diffusion Coefficient (ADC) value was measured by drawing manually regions of interest (ROI) on the ADC map; the ROIs were placed on the center of each Ln to reduce the possibility of signal contamination caused by the partial volume effect of the surrounding structures.

Ln's were classified also according to their location in the three main different lymphatic districts: mesorectal, presacral and lateral pelvic.

#### Histological analysis

Pathology evaluation of the surgical specimens was the standard reference for the histological parameters. Pathology reports were reviewed to determine the tumour T stage and N stage according to the 7<sup>th</sup> edition of TNM classification [15].

#### Statistical analysis

Concordance between different qualitative (categorical) items classified in two different

ways was measured by Cohen's kappa coefficient with linear weighting  $k_w$  ( $0 \le k_w \le 1$ ). The performance of MR in correctly staging tumours and Ln was assessed by cross correlating its outcome with the histological findings and computing, beside the kappa coefficient, also the five diagnostic parameters, i.e. sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive value computed with the relative 95% Confidence Interval (CI).

Categorical variables were compared with non chi-square or Fisher's exact test. The ADC distributions met the normality conditions according to the Kolmogorov-Smirnov/Lillienfors test and the Shapiro-Wilks W test: for greater confidence, their comparison was carried out besides ANOVA also with the non-parametric Mann-Whitney's and Kruskal-Wallis tests, respectively for 2 and 3 distributions. Statistical significance was set at two-tails p<0.05.

The discriminatory ability of ADC as indicator of high probability of malignancy (P3) was assessed by the Receiving Operating Characteristics (ROC) curve, a plot of True Positive Rate (Sensitivity) versus False Positive Rate (1-Specificity). The Area Under the Curve (AUC) measures the quality of discrimination: conventionally 0.6 corresponds to poor and 1 to excellent. The threshold for P3 was set at the ADC value for which both the harmonic mean (HM) of specificity and sensitivity and Cohen's coefficient k reached their maximum.

Open source software OpenEpi (<u>www.openepi.com</u>) and VassarStats (<u>www.vassarstats.net</u>) were used along with StatPlus:mac Pro (Analyst Soft Inc. Walnut, CA, US). All tests were run on at least two different packages.

#### **RESULTS**

#### T-stage

The inter-observer concordance on MR T-stage (cT) as measured by Cohen's coefficient was  $k_w$ =0.81±0.08. The end result was the cross-correlation table between MR (cT) and pathology (pT) reported as Table 1. The relative Cohen's concordance coefficient was  $k_w$ =0.89±0.06.

The comparison of the identification of mesorectal fat invasion by MR and histology yielded 24 true positive, 25 true negative, 3 false positive and 0 false negative interpretations. The diagnostic parameters were sensitivity 100 % (95%CI 86-100), specificity 89.3% (95%CI 73-96), diagnostic accuracy 94.2% (95%CI 84-98), positive predictive value 88.9% (95%CI 72-96) and negative predictive value 100% (95%CI 87-100).

#### N-stage

MR qualitative analysis recognized 265 Ln's. Our estimate of the probability of malignancy classified the Ln as follows: 198 P1, 17 P2 and 50 P3. Figure 1 shows as an example T2WI, DWI

(b600) and ADC map for a P1, P2 and P3 Ln.

Table 2 reports the cross-correlation table of the MR node stage (cN) for Ln's classified with score P3, i.e. with high probability of malignancy, versus pathology node staging (pN) for the 52 patients. Cohen's concordance coefficient was  $k_w$ =0.62±0.11.

The comparison of the ability of MR to classify the nodal staging (cN) with histology (pN) yielded 14 true positive, 26 true negative, 11 false positive and 1 false negative. The diagnostic parameters were sensitivity 93.3% (95%CI 70-99), specificity 70.2% (95%CI 54-83), diagnostic accuracy 76.9% (95%CI 64-86), positive predictive value 56% (95%CI 37-73) and negative predictive value 96.3% (95%CI 82-99).

The ADC value of the Ln's belonging to the three different classifications of probability of malignancy was  $1.23\pm0.30\times10^{-3}$  mm²/s for P1,  $1.12\pm0.31\times10^{-3}$  mm²/s for P2 and  $0.82\pm0.17\times10^{-3}$  mm²/s for P3 (p=0.0003). Since the ADC values for P1 and P2 were not significantly different (p=0.15), the two sets were pooled to form the low probability MTS Ln sample. The pooled ADC was  $1.22\pm0.30\times10^{-3}$  mm²/s significantly higher (p<0.0001) than the value relative to the high probability MTS Ln sample P3  $0.82\pm0.17\times10^{-3}$  mm²/s. The performance of ADC as possible discriminator was tested by the ROC curve procedure, obtaining and appreciably high AUC = 0.88 indicating a good-very good discrimination (Figure 2). High probability MTS Ln's were then found to correspond to ADC  $\leq 1.0\times10^{-3}$ mm²/s (Figure 3), with sensibility 90% and specificity 77.5%. ADC $\leq 1\times10^{-3}$ mm²/s held for 90% (45/50) of high probability malignant Ln's and for 22% (48/215) of low-moderate probability MTS Ln's (OR = 31, 95%CI 12-82.8; p<0.0001).

Of the 265 Ln identified, 153 were identified in the mesorectal district, 103 in the presacral and 9 in the lateral pelvic; the incidence of P3 in this last district was 5/9 (55.6%), significantly higher than in the mesorectum (27/153, 17.6%) and in the presacral (18/103, 17.5%) districts (p=0.02).

#### **DISCUSSION**

The results of the study herein presented allowed us to confirm the accuracy of MR for tumour (T) staging in patients with rectal cancer. We also obtained encouraging results on MR capability to correctly characterize Ln's and on the ability of ADC to discriminate between metastatic and non-metastatic Ln's.

Accurate determination of the T stage is important in rectal cancer because certain T3 and T4 tumours are treated when not contraindicated and accepted with neoadjuvant chemoradiation prior to resection. Our study demonstrates that the ability of MR to identify tumour mesorectal fat invasion, when compared to histology, is characterized by good diagnostic accuracy: 100%

sensitivity 100%, 89.3% specificity and overall 94.2% diagnostic accuracy, are in agreement with the literature showing 75-91%, 76-90%, and 77-86% data respectively [16-18].

Ln involvement is another indication for preoperative neoadjuvant chemoradiation, and this fact makes a reliable characterization of N stage a highly desirable requisite. To explore this feature, the MR outcome was expressed as P1, P2 or P3 according to the increasing probability of Ln metastases computed on the basis of dimension, irregular morphology and signal characteristics [4,5]. Considering only the high probability malignant Ln's (P3) our results indicate a particularly high sensitivity and specificity, with a considerable negative predictive value close to 100%. This is slightly better than literature were sensitivity ranges between 45 and 85%, but with high specificity, although accuracy, positive predictive value and negative predictive value waver around 70% [3,4,19]. Our very high negative predictive value is an important result, being crucial, if confirmed, for the choice of the most appropriate treatment, with impact on the potential risk for local tumour recurrence.

We also established the important role of the ADC. We found that the Ln's with high MTS probability (P3) had ADC =  $0.82\pm0.17\times10^{-3}$  mm<sup>2</sup>/s, significantly lower (p<0.0001) than the value  $1.22\pm0.30\times10^{-3}$  mm<sup>2</sup>/s for low and moderate MTS probability Ln's. The ROC curve procedure assessed the very good performance of ADC as discriminator between the two (AUC=0.88), determining ADC $\leq$ 1×10<sup>-3</sup>mm<sup>2</sup>/s as the values associated with high probability of MTS Ln (P3), with 90% sensibility and 78% specificity, and an OR = 31.

Our results on the association of ADC $\leq 1\times10^{-3}$ mm²/s with possible metastatic Lns and their classification confirm with a more powerful statistics the conclusions suggested by two previous studies [11,12]. Yasui et al. [11] observed that the mean ADC value was significantly lower for metastatic Ln's (1.36×10<sup>-3</sup>mm²/s) than for non-metastatic Ln's (1.85×10<sup>-3</sup>mm²/s). Cho et al. [12] found the same trend, with an ADC value of  $0.9\pm0.15\times10^{-3}$  mm²/s vs.  $1.1\pm0.22\times10^{-3}$  mm²/s for high risk and low risk groups respectively (p<0.0001). When they followed the ROC curve procedure (AUC=0.73) they identified the value of  $1.0\times10^{-3}$  mm²/s as cut off for ADC, with moderate sensitivity and specificity.

The low ADC values of malignant tissues are probably related to a combination of higher cellularity, tissue disorganization, and increased extracellular space tortuosity, all contributing to reduce the mobility of water. Low ADC values were associated also with a more aggressive rectal tumour profile [20] and with a better response to neoadjuvant chemoradiation [21].

The last result concerned the lateral pelvic Lns. It is well known that the lymphatic drainage of the upper rectum involves predominantly mesorectal lymphatics, with upward drainage along the inferior mesenteric artery. The lymphatic system of the lower rectum, in contrast to the upper

rectum, drains instead via lateral lymphatic vessels and this way it likely involves lateral pelvic Lns. In our series, although only 3.4% where located in the lateral pelvic district, they had very high risk to be metastatic (55.6%); those data are important because suspicious metastatic Ln in the lateral pelvic area are a risk factor for loco-regional recurrence in patients who have undergone curative resection with preoperative concurrent chemo-radiotherapy [22].

Our study has some limitations. First it was a retrospective review of a limited number of examinations on a patient-per-patient basis. Furthermore, sometimes it is difficult to indicate which of the Ln was truly positive in patients with nodal involvement, but the good correlation with pathology achieved make us confident of right matching.

#### **CONCLUSION**

In conclusion, our study shows that MR is certainly an accurate imaging method in T staging and N staging of rectal cancer cases, allowing reliable prediction of nodal involvement by considering dimension, morphology and signal characteristic. The association with low ADC value and high probability malignant nodes suggests the importance of the routine use of MR with DWI in the diagnostic process.

#### **REFERENCES**

- 1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2104;64:9–29.
- 2. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–17.
- 3. Hwang K, Park IJ, Yu CS, Lim S-B, Lee JL, Yoon YS, et al. Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer. World J Gastroenterol 2015;21:563–70.
- 4. Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003;227:371–7.
- 5. Kim JH, Beets GL, Kim M-J, Kessels AGH, Beets-Tan RGH. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol 2004;52:78–83.
- 6. Arezzo A, Bianco F, Agresta F, Coco C, Faletti R, Krivocapic Z, et al. Practice parameters for early rectal cancer management: Italian Society of Colorectal Surgery (Società Italiana di Chirurgia Colo-Rettale; SICCR) guidelines. Tech Coloproctology 2015;19:587–93.
- 7. Bianco F, Arezzo A, Agresta F, Coco C, Faletti R, Krivocapic Z, et al. Practice parameters for early colon cancer management: Italian Society of Colorectal Surgery (Società Italiana di Chirurgia Colo-Rettale; SICCR) guidelines. Tech Coloproctology 2015;19:577–85.
- 8. Choi AH, Nelson RA, Schoellhammer HF, Cho W, Ko M, Arrington A, et al. Accuracy of computed tomography in nodal staging of colon cancer patients. World J Gastrointest Surg 2013;7:116–22.
- 9. Mizukami Y, Ueda S, Mizumoto A, Sasada T, Okumura R, Kohno S, et al. Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer. World J Surg 2011;35:895–9.
- 10. Heijnen LA, Lambregts DMJ, Mondal D, Martens MH, Riedl RG, Beets GL, et al. Diffusion-weighted MR imaging in primary rectal cancer staging demonstrates but does not characterise lymph nodes. Eur Radiol 2013;23:3354–60.
- 11. Yasui O, Sato M, Kamada A. Diffusion-weighted imaging in the detection of lymph node metastasis in colorectal cancer. Tohoku J Exp Med 2009;218:177–83.
- 12. Cho EY, Kim SH, Yoon J-H, Lee Y, Lim Y-J, Kim S-J, et al. Apparent diffusion coefficient for discriminating metastatic from non-metastatic lymph nodes in primary rectal cancer. Eur J Radiol 2013;82:e662–8.
- 13. Lahaye MJ, Engelen SME, Kessels AGH, de Bruïne AP, von Meyenfeldt MF, van

- Engelshoven JMA, et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 2008;246:804–11.
- 14. Beets-Tan RGH, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Caseiro-Alves F, et al. Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2013;23:2522–31.
- 15. Leslie H. Sobin, Mary K. Wiley: TNM Classification of Malignant Tumours, 7th Edition, 2007
- 16. Fernández-Esparrach G, Ayuso-Colella JR, Sendino O, Pagés M, Cuatrecasas M, Pellisé M, et al. EUS and magnetic resonance imaging in the staging of rectal cancer: a prospective and comparative study. Gastrointest Endosc 2011;74:347–54.
- 17. Rao S-X, Zeng M-S, Xu J-M, Qin X-Y, Chen C-Z, Li R-C, et al. Assessment of T staging and mesorectal fascia status using high-resolution MRI in rectal cancer with rectal distention. World J Gastroenterol 2007;13:4141–6.
- 18. Fütterer JJ, Yakar D, Strijk SP, Barentsz JO. Preoperative 3T MR imaging of rectal cancer: local staging accuracy using a two-dimensional and three-dimensional T2-weighted turbo spin echo sequence. Eur J Radiol 2008;65:66–71.
- 19. Zhou J, Zhan S, Zhu Q, Gong H, Wang Y, Fan D, et al. Prediction of nodal involvement in primary rectal carcinoma without invasion to pelvic structures: accuracy of preoperative CT, MR, and DWIBS assessments relative to histopathologic findings. PloS One 2014;9:e92779.
- 20. Curvo-Semedo L, Lambregts DMJ, Maas M, Beets GL, Caseiro-Alves F, Beets-Tan RGH. Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Magn Reson Imaging 2012;35:1365–71.
- 21. Jung SH, Heo SH, Kim JW, Jeong YY, Shin SS, Soung M-G, et al. Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging. J Magn Reson Imaging 2012;35:110–6.
- 22. Kim TH, Jeong S-Y, Choi DH, Kim DY, Jung KH, Moon SH, et al. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol 2008;15:729–37.

#### FIGURES CAPTION

Figure 1. T2WI, DWI (b600) and ADC map for a P1 (first line), P2 (second line) and P3 (third line) Ln.

Figure 2. ROC curve procedure to test the discriminating ability of ADC between high probability and low probability of Ln MTS; Area Under the Curve (AUC) = 0.88.

Figure 3. Plot of harmonic mean (HM) of sensitivity and specificity and k (Cohen's coefficient) as a function of ADC: their maximum indicates the ADC threshold. The ADC values are  $1 \times 10^{-3}$  mm<sup>2</sup>/s.

Table 1. Cross-correlation table between MR (cT) and pathology (pT)

M	R cT1	cT2	сТ3	cT4
AP				
pT1	6	1		
pT2	1	17	3	
рТ3			20	
pT4				4

Table 2. Cross-correlation table of MR(cN) versus pathology (pN) for the 52 patients.

RM	cN0	cN1	cN2
AP			
pN0	26	11	
pN1	1	12	
pN2		2	





